使用包封的单链抗体诱导抗独特型体液免疫和细胞免疫反应。

Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses.

作者信息

Ma J, Luo D, Kwon G S, Samuel J, Noujaim A A, Madiyalakan R

机构信息

Research and Development, AltaRex Corp., 300, 8625-112 Street, Edmonton, Alberta, Canada.

出版信息

J Pharm Sci. 1998 Nov;87(11):1375-8. doi: 10.1021/js9800681.

DOI:10.1021/js9800681

PMID:9811493

Abstract

The use of biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres as a cancer vaccine delivery system for induction of anti-idiotypic responses has been investigated using a single chain antibody scFv-pDL10, which recognizes the human ovarian cancer antigen CA125. Immunization of mice with scFv-pDL10 encapsulated in PLGA microspheres resulted in enhanced humoral and cellular immune responses when compared to scFv-pDL10 alone. Induced anti-idiotypic antibodies (Ab2) which mimic the original antigen CA125 compete with CA125 for the epitope. A cellular response (T2 induction) was also observed. These results raise the possibility of anti-idiotypic antibody induction by a single chain antibody, encapsulated in biodegradeble microspheres, as a potential vaccine for ovarian carcinoma.

摘要

已经使用识别人类卵巢癌抗原CA125的单链抗体scFv-pDL10，研究了将可生物降解的聚乳酸-乙醇酸共聚物（PLGA）微球用作癌症疫苗递送系统以诱导抗独特型反应。与单独的scFv-pDL10相比，用封装在PLGA微球中的scFv-pDL10免疫小鼠可增强体液免疫和细胞免疫反应。诱导产生的模拟原始抗原CA125的抗独特型抗体（Ab2）与CA125竞争表位。还观察到了细胞反应（T2诱导）。这些结果增加了通过封装在可生物降解微球中的单链抗体诱导抗独特型抗体作为卵巢癌潜在疫苗的可能性。